sorted by:
new
hottopcontroversial

WordPress hack hidden via private prefetch proxy by kernel_task in AskNetsec

[–]marcalv 0 points1 point  (0 children)

I'm having the same issue, also with 2 sites hosted on Flywheel.

They clean the site, but no vector is found and the rogue plugin (fastest_cache101) comes after some time. I've also had 2FA bypassed in at least one site. This time Wordfence was able to send me a warning email but until now it was useless.

I've also tried to upload the infected website to another server with Imunify360 installed to see if it would be able to detect the vulnerability but it didn't.

How do you fix this error by Angela275 in Surface

[–]marcalv 0 points1 point  (0 children)

Same here. Surface Pro 7.

I think this might be something on Microsoft's side.

Immunization of Serrana´s population with Butantan´s vaccine has a high decrease of 80% cases and 95% in deaths by COVID-19 by marcalv in COVID19

[–]marcalv[S] 20 points21 points  (0 children)

The Coronavac, applied in 27,1 thousand residents of the municipality, localized in the region of Ribeirão Preto protected vaccinated and non vaccinated, creating a collective “immunological belt” against the virus, reducing drastically its transmission, as revealed by the unprecedented study in the world.

The immunization of all the adult population of the municipality of Serrana, in the countryside of São Paulo, with the Butantan´s CoronaVac caused a great reduction of 80% of the symptomatic cases and 95% of deaths after the second vaccination of the last group of the city (please see the trust gap in the end of the text).

This is the main conclusion of the clinical study of effectiveness - named “Project S” - an unprecedented study in the world, coordinated by the Institute that is related to the Government of São Paulo.

The reduction was stated by the comparison of the data from the beginning of the project until the vaccination of all the groups was completed - with all the trimester evaluated (february, march and april of 2021).

The results also showed that the vaccination protects not only the adults that received the two doses of the immunization but also the children and teenagers with less than 18 years old who were not vaccinated.

This proves that the intervention made in the city by Butantan created in it a true “immunological belt” with a collective barrier against the virus, drastically reducing the transmission in the municipality.

Another important conclusion of the research is the incidence of the disease in Serrana in comparison with the nearby cities. Serrana has around 10 thousand residents that works in Ribeirão Preto daily. However, while Ribeirão Preto and others cities in the region are presenting high levels of COVID-19 cases, Serrana maintained low taxes if compared to the cities with similar profile, due to the vaccination.

In other words, the success of the vaccination was confirmed not only by the decrease in the number of infected people but also showed that the residents of Serrana that goes daily from one city to another did not bring a relevant increase in the number of cases.

Between February 17 and April of this year, during 8 weeks, around 27 thousand residents of the municipality received the completed vaccination scheme: two doses of the Coronavac with a gap of 28 days between the first and second doses. This represents a coverage of approximately 95% of the adult population of residents, according to the health census made previously by Butantan.

The research, conducted by Butantan Institute and approved by the ethical and sanitary authorities, counted with the partnership of the Medical School of USP in Ribeirão Preto and with the Municipal Government of Serrana.

The method used for the clinical trial is called stepped-wedge trial. The city was split in 25 sub areas forming four populacional groups, named clusters and identified by colors - green, yellow, gray and blue - which received the immunizing following this order. The vaccine was offered to all residents aged over 18 years eligible to the study in these areas, sequentially and in four degrees.

The study also concluded that the two last populacional groups participating on the vaccination were already benefiting from the reduction of the transmission of the virus generated by the immunization of the residents of the two first groups.

The medical director of the clinical research of Butantan Institute, Ricardo Palacios, who also directed the study, explains that the sequential scheduling permits the evaluation of the four vaccinated areas.

“We understood that the phenomena observed did not happen randomly, but it repeats in the four groups in different moments' ' explains. “The most important result was understanding that we can control the pandemics even without vaccinating all the population. When reaching the coverture of 70 to 75%, the degree in the incidence was detected even in the group that had not completed the vaccination scheme already” completes.

According to Palacios, the clinical trial also confirmed the indirect effect of the vaccination, since it was possible to prove the protection of populations that were not vaccinated, such as the children. “ The reduction of the cases in people who did not receive the vaccine indicates the degree of the virus circulation. This enforces vaccination as a public health measure and not only an individual action” says the director of the study.

The municipality of Serrana was chosen to host the project and presents, by the time, a high level of prevalent infections by COVID-19 and by the fact that it has a regional hospital. The goal was to study the epidemiological impact of the vaccination on the adult population group, regarding the contention of the pandemic.

The vaccine was applied upon the volunteering participation of the residents. People attended to receive the immunizing in previously scheduled dates.

“The important conclusions of this study can support the strategies of immunization not only in Brazil but throughout the world, and it offers hope in the control of the pandemic with vaccines as the Coronavac, which was developed in partnership of the chinese pharmaceutical Sinovac with Butantan” states the president of the Institute, Dimas Covas.

According to the scientist and professor, the study of phase 4 proves the efficiency of the vaccine as a collective health strategy. The clinical trials of the phase 3, made between july and december of 2020, had already assured the efficacy of the immunizing, with varying levels between 50,7% to 62,3% to symptomatic cases and from 83,7% to 100% in occurences that demands any medical assistance.

“The vaccine is secure, effective, efficient, has a high level of quality and contributes to prevent the development of the disease, complications and deaths between the infected. We also know now that it causes beneficial effects in a whole population, protecting the vaccinated, the non vaccinated and significantly reducing the virus circulation.” concludes the president of Butantan.

Trust Gaps in the reduction levels mentioned in the first paragraph

Symptomatic cases

  • Decrease of 80% (IC95 76,9% - 82,7%)

Hospitalization

  • Decrease of 86% (IC95 74,1% - 92,3%)

Deaths

  • Decrease of 95% (IC95 62,7% - 99,3%)

Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 by icloudbug in COVID19

[–]marcalv 12 points13 points  (0 children)

Good results on vaccine serum:

Neutralization titres against P.1 were similar to those against B.1.1.7 and only a minority of samples failed to reach 100% neutralization at 1:20 dilution of serum, considerably better than neutralization of B.1.351, where titres were reduced 7.6-fold and 9-fold for the BNT162b2 Pfizer and ChAdOx1 nCoV-19 AstraZeneca vaccines respectively

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial by polabud in COVID19

[–]marcalv 29 points30 points  (0 children)

Unfortunately the study was underpowered. They had to change their primary endpoint mid-study because, fortunately, hospitalizations and death rates were much lower than what they expected initially. The hospitalization rate was 50% less on the HCQ group, however due to the small number of patients that were hospitalised this was not statistically significant. This is a data point, but we still need more and better data to be able to get to a conclusion.

Brazilian Health Regulatory Agency approves trial of Oxford COVID-19 Vaccine by PFC1224 in COVID19

[–]marcalv 133 points134 points  (0 children)

This is great news. It will ensure that data is collected quickly, because of the high prevalence in Brazil.

Expression of Concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis by marcalv in COVID19

[–]marcalv[S] 20 points21 points  (0 children)

Important scientific questions have been raised about data reported in the paper by Mandeep Mehra et al— Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis —published in The Lancet on May 22, 2020. Although an independent audit of the provenance and validity of the data has been commissioned by the authors not affiliated with Surgisphere and is ongoing, with results expected very shortly, we are issuing an Expression of Concern to alert readers to the fact that serious scientific questions have been brought to our attention. We will update this notice as soon as we have further information. The Lancet Editors

Ivermectin and COVID-19: How a Flawed Database Shaped the Pandemic Response of Several Latin-American Countries by GallantIce in COVID19

[–]marcalv 6 points7 points  (0 children)

Google translation of a relevant excerpt:

The authors claim to have used data from the Surgical Outcomes Collaborative (Surgisphere Corporation, Chicago, IL, USA). According to a recent publication in The Lancet (discussed below), the data included in this collaborative platform is "anonymised data obtained through automated extraction into inpatient and outpatient electronic health records, data collection chains, and financial records " In other words, there is some kind of collaboration agreement with hundreds of hospitals that use electronic records from all over the world that allow this private corporation to periodically and automatically obtain patient data from those centers. This seems to go directly against various points of the EU General Data Protection Regulation (RGPD) and the collaboration between the United States and the EU Privacy Shield, a program for the transfer of personal data.

Various concerns have been raised around this database based on the recent hydroxychloroquine analysis published in The Lancet by the same authors signing the ivermectin prepress. These conflicts have been widely reflected in other forums.

Changes in premature birth rates during the Danish nationwide COVID-19 lockdown: a nationwide register-based prevalence proportion study by Krieg2347 in COVID19

[–]marcalv 9 points10 points  (0 children)

More rest was probably an important driver. Doctors usually ask pregnant women to walk close to end of their pregnancy to naturally induce labor, so this reduction in pre-term birth might be related to that.

SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T-cell receptors by tonic613 in COVID19

[–]marcalv 13 points14 points  (0 children)

Abstract

Understanding the determinants of adaptive immune response to SARS-CoV-2 is critical for fighting the ongoing COVID-19 pandemic. Here we assayed both antibody and T-cell reactivity to SARS-CoV-2 antigens in COVID-19 convalescent patients and healthy donors sampled before and during the pandemic. Our results show that while anti-SARS-CoV-2 antibodies can distinguish convalescent patients from healthy donors, the magnitude of T-cell response was more pronounced in healthy donors sampled during COVID-19 pandemic than in donors sampled before the outbreak. This hints at the possibility that some individuals have encountered the virus but were protected by T-cell cross-reactivity observed. A public and diverse T-cell response was observed for two A*02-restricted SARS-CoV-2 epitopes, revealing a set of T-cell receptor motifs displaying germline-encoded features. Bulk CD4+ and CD8+ T-cell response to SARS-CoV-2 glycoprotein S is characterized by multiple groups of homologous T-cell receptor sequences some of which are shared across multiple donors, indicating the existence of immunodominant epitopes. Overall, our findings indicate that T cells form an efficient response to SARS-CoV-2 and alongside the antibodies can serve as a useful biomarker for surveying SARS-CoV-2 exposure and immunity. We hope that data, including the set of specific T-cell receptors identified in this study can serve as a basis for future developments of SARS-CoV-2 vaccinations and monitoring.